LifeMD Q4 2023 Adj EPS $0.15 Beats $(0.14) Estimate, Sales $44.860M Beat $40.494M Estimate
Portfolio Pulse from Benzinga Newsdesk
LifeMD (NASDAQ:LFMD) reported Q4 2023 adjusted EPS of $0.15, surpassing the $(0.14) estimate, with sales of $44.860M beating the $40.494M estimate, a 59.53% increase from the previous year.
March 11, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LifeMD reported a significant beat on both EPS and sales estimates for Q4 2023, with a notable year-over-year sales growth.
Beating both EPS and sales estimates by a wide margin, especially with a substantial year-over-year sales increase, is a strong positive signal for the company. This performance is likely to boost investor confidence and could lead to a short-term uptick in LFMD's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100